Summary of Product Characteristics (SmPC) - Baclofen tablets BP 10 mg
1 NAME OF THE MEDICINAL PRODUCT
Baclofen Tablets BP 10mg.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Baclofen 10 mg.
Excipient(s) with known effect: Lactose monohydrate: 40 mg per tablet
Sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, i.e. is essentially ‘sodium-free’.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
White round, flat bevelled edge tablet marked "BN" breakline "10" on one side and plain on the reverse.
4.1 Therapeutic indications
Baclofen is indicated for the relief of spasticity of voluntary muscle resulting from such disorders as multiple sclerosis, other spinal lesions, e.g. tumours of the spinal cord, syringomyelia, motor neurone disease, transverse myelitis, traumatic partial section of the cord.
Baclofen is also indicated in adults and children for the relief of spasticity of voluntary muscle arising from e.g. cerebrovascular accidents, cerebral palsy, meningitis, traumatic head injury.
Paediatric population
Baclofen is indicated in patients 0 to <18 years for the symptomatic treatment of spasticity of cerebral origin, especially where due to infantile cerebral palsy, as well as following cerebrovascular accidents or in the presence of neoplastic or degenerative brain disease.
Baclofen is also indicated for the symptomatic treatment of muscle spasms occurring in spinal cord diseases of infectious, degenerative, traumatic, neoplastic, or unknown origin such as multiple sclerosis, spastic spinal paralysis, amyotrophic lateral sclerosis, syringomyelia, transverse myelitis, traumatic paraplegia or paraparesis and compression of the spinal cord.
Patient selection is important when initiating baclofen therapy; it is likely to be of most benefit in patients whose spasticity constitutes a handicap to activities and/or physiotherapy. Treatment should not be commenced until the spastic state has become stabilised.
4.2 Posology and method of administration
Dosage
Baclofen is given orally in either tablet or liquid form. These two formulations are bioequivalent. The liquid may be particularly suitable for children or those adults who are unable to take tablets. Dosage titration can be more precisely managed with the liquid. The lowest dose compatible with an optimal
response is recommended.
Before starting treatment with Baclofen it is prudent to realistically assess the overall extent of clinical improvement that the patient may be expected to achieve. Careful titration of dosage is essential (particularly in the elderly) until the patient is stabilised. If too high a dose is initiated or if the dosage is increased too rapidly side effects may occur. This is particularly relevant if the patient is ambulant in order to minimise muscle weakness in the unaffected limbs or where spasticity is necessary for support.
Once the maximum recommended dose has been reached, if the therapeutic effect is not apparent within 6 weeks a decision whether to continue with Baclofen should be taken.
Discontinuation of the treatment should always be gradual by successively reducing the dosage over a period of approximately 1 to 2 weeks, except in overdose-related emergencies, or where serious adverse effects have occurred (see section 4.4).
Adults
Treatment should be started with a dosage of 15 mg daily, preferably in divided doses. The following gradually increasing dosage regime is suggested but should be adjusted to suit individual patient requirements.
5 mg 3 times a day for 3 days
10 mg 3 times a day for 3 days
15 mg 3 times a day for 3 days
20 mg 3 times a day for 3 days
Satisfactory control of symptoms is usually obtained with doses up to 60 mg daily, but a careful adjustment is often necessary to meet the requirements of each individual patient.
The dose may be increased slowly if required, but a maximum daily dose of more than 100 mg is not advised unless the patient is in hospital under careful medical supervision. Small frequent dosage may prove better in some cases than larger spaced doses.
Also some patients benefit from the use of baclofen only at night to counteract painful flexor spasm. Similarly a single dose given approximately one hour prior to the performance of specific tasks such as washing, dressing, shaving, physiotherapy, will often improve mobility.
Special populations
Elderly patients (aged 65 years or above):
Elderly patients may be more susceptible to side-effects, particularly in the early stages of introducing baclofen. Small doses should therefore be used at the start of the treatment, the dose being titrated gradually against the response, under careful supervision. There is no evidence that the eventual average maximum dose differs from that in younger patients.
Paediatric population (0 to<18 years)
Treatment should usually be started with a very low dose (corresponding to approximately 0.3mg/kg a day), in 2-4 divided doses, preferably in 4 divided doses. The dosage should be cautiously raised, at about 1 week intervals, until it becomes sufficient for the child’s individual requirements. The usual daily doses for maintenance therapy ranges between 0.75 and 2mg/kg body weight. The total daily dose should not exceed a maximum of 40mg/day in children below 8 years of age. In children over 8 years of age a maximum daily dosage of 60mg/day may be given. Baclofen tablets are not suitable for the use in children below 33kg body weight.
Patients with impaired renal function: In patients with impaired renal function or undergoing chronic haemodialysis, a particularly low dosage of baclofen should be selected i.e. approx. 5 mg daily. Baclofen should be administered to end stage renal failure patients should be closely monitored for prompt diagnosis of early signs and/or symptoms of toxicity (e.g. somnolence, lethargy) (see section 4.4 and section 4.9).Signs of overdose have been observed in patients with renal impairment treated with more than 5 mg oral baclofen per day.
Patients with hepatic impairment:
No studies have been performed in patients with hepatic impairment receiving baclofen therapy. The liver does not play a significant role in the metabolism of baclofen after oral administration of baclofen (see section 5.2). However, baclofen has the potential of elevating liver enzymes. baclofen should be prescribed with caution in patients with hepatic impairment.
Patients with spastic states of cerebral origin: Unwanted effects are more likely to occur in these patients. It is therefore recommended that a cautious dosage schedule be adopted and that the patients be kept under appropriate surveillance.
Method of administration
Baclofen is given orally.
4.3 Contraindications
- Hypersensitivity to baclofen or to any of the excipients listed in section 6.1
- Peptic ulceration.
4.4 Special warnings and special precautions for use
Psychiatric and nervous system disorders
Porphyria, history of alcoholism, hypertension, psychotic disorders, schizophrenia depressive or manic disorders, confusional states or Parkinson's disease may be exacerbated by treatment with baclofen. Patients suffering from these conditions should therefore be treated cautiously and kept under close surveillance. Suicide and suicide-related events have been reported in patients treated with baclofen. In most cases, the patients had additional risk factors associated with an increased risk of suicide including alcohol use disorder, depression and/or a history of previous suicide attempts. Close supervision of patients with additional risk factors for suicide should accompany drug therapy. Patients (and caregivers of patients) should be alerted about the need to monitor for clinical worsening, suicidal behaviour or thoughts or unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
Cases of misuse, abuse and dependence have been reported with baclofen. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of baclofen misuse, abuse or dependence e.g. dose escalation, drug-seeking behaviour, development of tolerance.
Epilepsy
Baclofen may also exacerbate epileptic manifestations but can be employed provided appropriate supervision and adequate anticonvulsive therapy are maintained.
Encephalopathy
Cases of encephalopathy have been reported in patients receiving baclofen at therapeutic doses, which were reversible after treatment discontinuation. Symptoms included somnolence, depressed level of consciousness, confusion, myoclonus and coma. (see section 4.8 and 4.9)
If signs of encephalopathy are observed, baclofen should be discontinued.
Others
Baclofen should be used with extreme care in patients already receiving anti-hypertensive therapy (see section 4.5).
Baclofen should be used with caution in patients suffering from cerebrovascular accidents or from respiratory or hepatic impairment.
Since unwanted effects are more likely to occur, a cautious dosage schedule should be adopted in elderly and patients with spasticity of cerebral origin (see section 4.2).
Renal impairment
Neurological signs and symptoms of overdose including clinical manifestations of toxic encephalopathy (e.g. confusion, disorientation, somnolence and depressed level of consciousness) have been observed in patients with renal impairment taking oral baclofen at dose of more than 5 mg per day and at doses of 5mg per day in patients with end-stage renal failure being treated with chronic hemodialysis. Patients with impaired renal function should be closely monitored for prompt diagnosis of early symptoms of toxicity.
Baclofen should be used with caution in patients with renal insufficiency and should be administered to patients with end-stage renal failure (CKD stage 5, GFR <15mL/min) only if the expected benefit outweighs the potential risk (see section 4.2).
Cases of baclofen toxicity have been reported in patients with acute renal failure (see section 4.9).
Particular caution is required when combining baclofen to drugs or medicinal products that can significantly affect renal function. Renal function should be closely monitored and baclofen daily dosage adjusted accordingly to prevent baclofen toxicity.
Besides discontinuing treatment, unscheduled haemodialysis might be considered as a treatment alternative in patients with severe baclofen toxicity. Haemodialysis effectively removes baclofen from the body, alleviates clinical symptoms of overdose and shortens the recovery time in these patients.
Urinary disorders
Under treatment with Baclofen neurogenic disturbances affecting emptying of the bladder may show an improvement. In patients with pre-existing sphincter hypertonia, acute retention of urine may occur; the drug should be used with caution in such cases.
Laboratory tests
In rare instances elevated aspartate aminotransferase (AST), blood alkaline phosphatase and blood glucose levels in serum have been recorded. Appropriate laboratory tests should be performed in patients with liver diseases or diabetes mellitus in order to ensure that no drug induced changes in these underlying diseases have occurred.
Abrupt withdrawal
Treatment should always, (unless serious adverse effects occur), be gradually discontinued by successively reducing the dosage over a period of about 1-2 weeks. Anxiety and confusional state, delirium, hallucination, psychotic disorder delusions, mania or paranoia, convulsions (status epilepticus), dyskinesia, tachycardia, hyperthermia, rhabdomyolysis and temporary aggravation of spasticity and hypertonia have been reported with abrupt withdrawal of baclofen, especially after long term medication.
Drug withdrawal reactions including postnatal convulsions in neonates have been reported after intrauterine exposure to oral baclofen (see section 4.6).
Treatment should always (unless serious adverse effects occur), therefore, be gradually discontinued by successively reducing the dosage over a period of about one to two weeks.
Paediatric patients
There is very limited clinical data on the use of Baclofen in children under the age of one year. Use in this patient population should be based on the physician’s consideration of individual benefit and risk of therapy.
Posture and balance
Baclofen should be used with caution when spasticity is needed to sustain upright posture and balance in locomotion (see section 4.2).
Excipients
Contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Levodopa/dopa decarboxylase (DDC) inhibitor (Carbidopa)
In patients with Parkinson’s disease receiving treatment with baclofen and levodopa (alone or in combination with DDC inhibitor, carbidopa), there have been reports of mental confusion, hallucinations, nausea and agitation. Worsening of the symptoms of Parkinsonism has also been reported. Hence, caution should be exercised during concomitant administration of baclofen and levodopa/carbidopa.
Drugs causing Central Nervous System (CNS) depression
Increased sedation may occur when baclofen is taken concomitantly with other drugs causing CNS depression including other muscle relaxants (such as tizanidine), with synthetic opiates or with alcohol (see section 4.7).
The risk of respiratory depression is also increased. In addition, hypotension has been reported with concomitant use of morphine and intrathecal baclofen. Careful monitoring of respiratory and cardiovascular functions is essential especially in patients with cardiopulmonary disease and respiratory muscle weakness.
Antidepressants
During concomitant treatment with tricyclic antidepressants, the effect of baclofen may be potentiated, resulting in pronounced muscular hypotonia. Lithium
Concomitant use of oral baclofen and lithium resulted in aggravated hyperkinetic symptoms. Thus, caution should be exercised when baclofen is used concomitantly with lithium.
Antihypertensives and other drugs known to lower blood pressure
Since concomitant treatment with baclofen and drugs that lower the blood pressure is likely to increase the fall in blood pressure, the dosage of concomitant medication should be adjusted accordingly.
Agents reducing renal function
Drugs or medicinal products that can significantly affect renal function may reduce baclofen excretion leading to toxic effects (see section 4.4).
4.6 Fertility, pregnancy and lactation
Pregnancy
During pregnancy, especially in the first three months, baclofen should only be employed if its use is of vital necessity. The benefits of the treatment for the mother must be carefully weighed against the possible risks for the child. Baclofen crosses the placental barrier.
Foetal/neonatal adverse reactions
Drug withdrawal reactions including postnatal convulsions in neonates have been reported after intra-uterine exposure to oral baclofen (see section 4.4). Breast-feedingIn mothers taking baclofen in therapeutic doses, the active substance passes into the breast milk, but in quantities so small that no undesirable effects in the infant are to be expected.
4.7 Effects on ability to drive and use machines
Baclofen may be associated with adverse effects such as dizziness, sedation, somnolence and visual impairment (see section 4.8) which may impair the patient’s reaction. Patients experiencing these adverse effects should be advised to refrain from driving or using machines.
4.8 Undesirable effects
Adverse effects occur mainly at the start of treatment (e.g. sedation, somnolence and nausea), if the dosage is raised too rapidly, if large doses are employed or in elderly patients. They are often transitory and can be attenuated or eliminated by reducing the dosage; they are seldom severe enough to necessitate withdrawal of the medication.
Should nausea persist following a reduction in dosage, it is recommended that baclofen be ingested with food or a milk beverage.
In patients with a history of psychiatric illness or with cerebrovascular disorders (e.g. stroke) as well as in elderly patients, adverse reactions may assume a more serious form.
Lowering of the convulsion threshold and convulsions may occur, particularly in epileptic patients.
Certain patients have shown increased spasticity as a paradoxical reaction to the medication.
An undesirable degree of muscular hypotonia – making it more difficult for patients to walk or fend for themselves – may occur and can usually be relieved by re-adjusting the dosage (i.e. by reducing the doses given during the day and possibly increasing the evening dose).
Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥1/10); common (>1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000) and not known (frequency cannot be determined from available data).
Table 1 Tabulated summary of adverse drug reactions
Immune System disorders
Not known: Hypersensitivity
Nervous system disorders
Very common: Somnolence, sedation
Common: Respiratory depression, confusional state, dizziness, hallucinations, depression, fatigue, insomnia, euphoric mood, muscular weakness, headache, ataxia, tremor, nightmares, myalgia, nystagmus, dry mouth Rare: Paraesthesia, dysarthria, dysgeusia
Not known: Sleep Apnoea syndrome* ,Encephalopathy
Eye disorders
Common: Accommodation disorders, visual impairment
Cardiac disorders
Common: Cardiac output decreased
Not known: Bradycardia
Vascular disorders
Common: Hypotension
Gastrointestinal disorders
Very common: Nausea,
Common: Gastrointestinal disorder, retching, vomiting, constipation, diarrhoea Rare: Abdominal pain
Hepatobiliary disorders
Rare: Hepatic function abnormal
Skin and subcutaneous tissue disorders
Common: Hyperhidrosis, rash
Not known: Urticaria, alopecia
Renal and urinary disorders
Common: Pollakiuria, enuresis, dysuria
Rare: Urinary retention
Reproductive system and breast disorders
Rare: Erectile dysfunction
Non Known: Sexual dysfunction
General disorders and administration site conditions Very rare: Hypothermia
Not known: Drug withdrawal syndrome* (see section 4.4),swelling face and peripheral oedema
Investigations
Not known: Blood glucose increased
* Drug withdrawal syndrome including postnatal convulsions in neonates has also been reported after intra-uterine exposure to oral baclofen. * Cases of central sleep apnoea syndrome have been observed with baclofen at high doses (≥ 100 mg) in patients who are alcohol dependent.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Symptoms: Prominent features are signs of central nervous depression or encephalopathy: somnolence, depressed level of consciousness, respiratory depression, coma and tinnitus.
Also liable to occur are confusion, hallucinations, agitation, abnormal electroencephalogram (burst suppression pattern and triphasic waves, generalised slowing on EEG), accommodation disorders, impaired pupillary reflex; generalised muscular hypotonia, myoclonus, hyporeflexia or areflexia, convulsions, peripheral vasodilation, hypotension, hypertension, bradycardia, tachycardia or cardiac arrhythmia, hypothermia, nausea, vomiting, diarrhoea, salivary hypersecretion, increased hepatic enzymes, sleep apnoea, rhabdomyolysis. Patients with renal impairment can develop signs of overdose even on low doses of oral baclofen (see section 4.2 and section 4.4).
A deterioration in the condition may occur if various substances or drugs acting on the central nervous system (e.g. alcohol, diazepam, tricyclic antidepressants) have been taken at the same time.
Treatment: No specific antidote is known.
Supportive measures and symptomatic treatment should be given for complications such as hypotension, hypertension, convulsions, gastrointestinal disorders and respiratory or cardiovascular depression.
Since the drug is excreted chiefly via the kidneys, generous quantities of fluid should be given, possibly together with a diuretic. Haemodialysis (sometimes unscheduled) may be useful in severe poisoning associated with renal failure (see section 4.4).
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antispastic with spinal site attack, ATC code: M03B X01
Baclofen is an antispastic agent acting at the spinal level.A gamma-aminobutyric acid (GABA) derivative, chemically unrelated to other antispastic agents.
Baclofen depresses monosynaptic and polysynaptic reflex transmission, probably by stimulating the GABAB -receptors. This stimulation in turn inhibits the release of the excitatory amino acids glutamate and aspartate. Neuromuscular transmission is unaffected by baclofen.
The major benefits of baclofen stem from its ability to reduce painful flexor spasms and spontaneous clonus thereby facilitating the mobility of the patient, increasing their independence and helping rehabilitation.
Baclofen also exerts an antinociceptive effect. General well being is often improved and sedation is less often a problem than with centrally acting drugs.
Baclofen stimulates gastric acid secretion.
5.2 Pharmacokinetic properties
Absorption: Baclofen is rapidly and completely absorbed from the gastro-intestinal tract. No significant difference between the liquid and tablet formulations is observed in respect of Tmax, Cmax and bioavailability.
Following oral administration of single doses (10-30mg) peak plasma concentrations are recorded after 0.5 to 1.5 hours and areas under the serum concentration curves are proportional to the dose.
Distribution: The volume of distribution of baclofen is 0.7 l/kg. The protein binding rate is approximately 30% and is constant in the concentration range of 10 nanogram/mL to 300 microgram/mL. In cerebrospinal fluid active substance concentrations are approximately 8.5 times lower than in the plasma.
Biotransformation: Baclofen is metabolised to only a minor extent. Deamination yields the main metabolite, β-(p-chlorophenyl)-4-hydroxybutyric acid, which is pharmacologically inactive.
Elimination/excretion: The plasma elimination half-life of baclofen averages 3 to 4 hours.
Baclofen is eliminated largely in unchanged form. Within 72 hours, approximately 75% of the dose is excreted via the kidneys with about 5% of this amount as metabolites.
Special populations
Elderly patients (aged 65 years or above)
The pharmacokinetics of baclofen in elderly patients are virtually the same as in patients below 65 years of age. Following a single oral dose, elderly patients have slower elimination but a similar systemic exposure of baclofen compared to adults below 65 years of age. Extrapolation of these results to multi-dose treatment suggests no significant pharmacokinetic difference between patients below 65 years of age and elderly patients ± 28.7 nanogram/mL, and Tmax in the range of 0.95-2 h have been reported. Mean plasma clearance (Cl) of 315.9mL/h/kg; volume of distribution (Vd) of 2.58 L/kg; and half life (T1/2) of 5.10 h have been reported.
Paediatric patients
Following oral administration of 2.5mg baclofen tablet in children (aged 2 to12 years), Cmax of 62.8±28.7 nanogram/mL, and Tmax in the range of 0.95-2 h have been reported. Mean plasma clearance (Cl) of 315.9mL/h/kg; volume of distribution (Vd) of 2.58 L/kg; and half-life (T1⁄2) of 5.10 h have been reported.
Hepatic impairment
No pharmacokinetic data are available in patients with hepatic impairment after administration of baclofen. However, as the liver dose not play a significant role in the disposition of baclofen, it is unlikely that baclofen pharmacokinetics would be altered to a clinically significant level in patients with hepatic impairment.
Renal impairment
No controlled clinical pharmacokinetic study is available in patients with renal impairment after administration of baclofen. Baclofen is predominately eliminated unchanged in urine. Sparse plasma concentration data collected only in female patients under chronic hemodialysis or compensated renal failure indicate significantly decreased clearance and increased half-life of baclofen in these patients. Dosage adjustment of baclofen based on its systemic levels should be considered in renal impairment patients, and prompt hemodialysis is an effective means of reversing excess baclofen in systemic circulation.
5.3 Preclinical safety data
Baclofen increases the incidence of omphaloceles (ventral hernias) in the foetuses of rats given approximately 13 times the maximum oral dose (on a mg/kg basis) recommended for human use. This was not seen in mice or rabbits.
An apparently dose related increase in the incidence of ovarian cysts and a less marked increase in enlarged and/or haemorrhagic adrenals have been observed in female rats treated for two years. The clinical relevance of these findings is not known.
Experimental evidence to date suggests that baclofen does not possess either carcinogenic or mutagenic properties.
6. PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Microcrystalline Cellulose
Lactose monohydrate
Calcium Hydrogen Phosphate Anhydrous
Colloidal Anhydrous Silica
Magnesium Stearate
Sodium Starch Glycollate (Type A)
6.2. Incompatibilities
None known.
6.3 Shelf life
Blister packs: 48 months
Polypropylene containers: 36 months
6.4. Special precautions for storage
Do not store above 25oC. Keep the container tightly closed. Store in the original container
6.5 Nature and contents of container
Polypropylene containers with polyethylene caps (with optional use of fillers)
Pack sizes: 5, 7, 10, 14, 15, 20, 21, 25, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 168, 180, 250, 500
Blister packs : 250µm PVC/PVdC and 25µm aluminium foil.
Pack sizes: 5, 7, 10, 14, 15, 20, 21, 25, 28, 30, 56, 60, 84, 90, 100, 112, 120, 168, 180
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No specific instructions for use/handling.
7. MARKETING AUTHORISATION HOLDER
Strides Pharma UK Ltd.
Unit 4, Metro Centre
Tolpits Lane
Watford
Hertfordshire
WD18 9SS
8 MARKETING AUTHORISATION NUMBER(S)
PL 13606/0066.
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
29th June 1998.
10 DATE OF REVISION OF THE TEXT
14/07/2025